On Friday, the pharmaceutical company Biogen announced the Food and Drug Administration accepted its application to conduct a priority review of their experimental Alzheimer’s drug for approval. The speedier-than-usual process sets the stage for the treatment, called aducanumab, to be the first new approved drug for the incurable, degenerative condition…
Now you can get the top stories from Gizmodo delivered to your inbox. Enter your email below.
By subscribing you agree to our Terms of Use and Privacy Policy.